Comparative Pharmacology
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus XYZAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYPROHEPTADINE HYDROCHLORIDE versus XYZAL.
CYPROHEPTADINE HYDROCHLORIDE vs XYZAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a potent antihistamine (H1 receptor antagonist) and antiserotonergic agent (5-HT2 receptor antagonist). It also exhibits weak anticholinergic and sedative properties. It blocks histamine-mediated vasodilation, increased capillary permeability, and pruritus, as well as serotonin-mediated effects on appetite and mood.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
4 mg orally three times daily; range 4-20 mg/day, not to exceed 0.5 mg/kg/day
5 mg orally once daily in the evening.
None Documented
None Documented
Terminal half-life approximately 8–16 hours in adults; may be prolonged in elderly or hepatic impairment.
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Primarily renal (appreciable unchanged drug and metabolites); biliary/fecal elimination minor (<5%).
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Category A/B
Category C
Antihistamine
Antihistamine